Research overview
BPC-157 (also coded PL 14736) is a synthetic peptide of 15 amino acids (GEPPPGKPADDAGLV), part of a larger protein its discoverers described in human gastric juice. Most published studies come from one research group at the University of Zagreb, Croatia, and almost all use injury models in rats or mice. For example, rats with cut Achilles tendons that were given BPC-157 had better strength, walking and tissue scores than controls (Staresinic et al., J Orthop Res 2003). Independent groups, including in Taiwan and China, have published far fewer studies.
Human data are very limited: three small uncontrolled pilot reports from one US author group, about 30 people in total (a look-back survey of knee pain patients, 12 women with a bladder pain condition, and a two-person safety check). None had a control group or used a standardised pharmaceutical product (Mateescu et al., Pharmaceutics 2026). The Zagreb group reported early clinical testing for inflammatory bowel disease under the code PL 14736, but no completed trial has been published. In rats and dogs its half-life in blood was under 30 minutes. Human pharmacokinetics, long-term safety and whether animal findings apply to people are not known. Supplied for laboratory research use only.
Mechanism of action
No single receptor for BPC-157 has been established, and the proposed mechanisms come from cell and rat studies. In human blood-vessel lining cells and in rats with restricted blood flow to a hind leg, BPC-157 raised levels of the growth-factor receptor VEGFR2 and switched on the Akt-eNOS pathway, which makes nitric oxide and is involved in forming new blood vessels (Hsieh et al., 2017). In cultured rat tendon cells it did not change how fast the cells multiplied but increased their spreading and migration, with activation of the FAK-paxillin pathway that anchors cells to their surroundings. The Zagreb group has also reported interactions with the nitric oxide, dopamine and serotonin systems in rats.
